10.1016/j.gendis.2022.11.022 Summary Keywords gemcitabine, resistance mechanism, tumor microenvironment, combination therapy, precision medicine Citation Zhang X, Qi B and Chen J (2025) Clinical application and drug resistance mechanism of gemcitabine
Winter SC, Szabo-Aczel S, Curry CJ, Hutchinson HT, Hogue R, Shug A: Plasma carnitine deficiency
the resulting working concentration (mg/ml) and the number of units on the scale are determined by the batch COA
CMS approved the use of freed up state funds for HRSN initiatives (in all states with DSHP expenditure authority) and approved limited other uses (e.g., reentry and workforce initiatives) that varied across state approvals
Third-party Certificate of Analysis (CoA)